<DOC>
	<DOCNO>NCT00420745</DOCNO>
	<brief_summary>This study plan evaluate safety ( term occurrence serious adverse event ) , reactogenicity ( side effect ) immunogenicity ( ability vaccine develop antibody fight infection ) HRV vaccine use pre-term infant age 6 14 week time first dose Portugal , France Poland pre-term infant age 6 12 week time first dose Spain . The study perform four European country ( France , Poland , Spain , Portugal ) . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>To Assess Safety , Reactogenicity &amp; Immunogenicity 2 Doses GSK 's Oral Human Rotavirus Vaccine Pre-Term Infants</brief_title>
	<detailed_description>This Phase 3b study . Each study group stratify two sub-groups depend gestational age birth subject : - Stratum I : pre-term infant , born gestational period 27-30 week ( 189-216 day ) ( 20 % enrolment ) . - Stratum II : mild pre-term infant born gestational period 31-36 week ( 217-258 day ) ( 80 % enrolment ) . The study conduct double-blind manner respect HRV vaccine placebo . The study blind respect type concomitantly administer routine infant vaccination . In accordance local National Plan Immunisation schedule respective participating country , GSK Biologicals ' Infanrix Hexa™ ( DTPa-HBV-IPV/Hib ) , Infanrix Quinta™ ( DTPa-IPV-Hib ) , Infanrix™+IPV+Hib ( DTPa+IPV+Hib ) and/or Engerix-B™ ( HBV ) co-administered ( maximum interval two day ) HRV vaccine placebo dose . Hepatitis B Bacille Calmette-Guérin vaccine ( BCG ) birth allow include local National Plan Immunisation schedule participate country . At discretion investigator follow vaccine may administer subject 's study participation : - Vaccine Streptococcus pneumoniae ( Prevenar® ) France Spain ( concomitantly HRV vaccine/Placebo ) . - Vaccine Neisseria meningitidis ( Neis Vacc C® ) allow least 14-days interval respect administration HRV vaccine/Placebo .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . Healthy male female infant , include , 6 14 week ( 42 104 day ) age time first study vaccination Portugal , France Poland . A male female infant , include , 6 12 week age time first study vaccination Spain . Medically stable preterm infant , bear within gestational period 27 36 week . Written inform consent obtain parent guardian subject . Planned discharge hospital 's neonatal stay day first HRV vaccine/Placebo administration . Use investigational nonregistered product ( drug vaccine ) HRV vaccine within 30 day precede first dose HRV vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol birth till study end . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Any clinically significant history chronic gastrointestinal disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness ( subject severe bronchopulmonary dysplasia require persistent oxygentherapy exclude ) . History neurologic disorder seizure . Grade I II intraventricular bleeding allow . Acute disease time enrolment . Administration immunoglobulins , and/or blood product within one month ( 30 day ) precede first dose study vaccine plan administration study period . Monoclonal antiRSV therapy/prophylaxis recombinant erythropoietin allow .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>14 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>